"Glucagon-Like Peptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms.
| Descriptor ID |
D004763
|
| MeSH Number(s) |
D06.472.317.469.500
|
| Concept/Terms |
Glucagon-Like Peptides- Glucagon-Like Peptides
- Glucagon Like Peptides
- Glucagon-Like Polypeptides
- Glucagon Like Polypeptides
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptides".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptides".
This graph shows the total number of publications written about "Glucagon-Like Peptides" by people in this website by year, and whether "Glucagon-Like Peptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
| 2024 | 2 | 1 | 3 |
| 2025 | 6 | 1 | 7 |
| 2026 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptides" by people in Profiles.
-
Comparison of Specific Glucagon-Like Peptide-1 Receptor Agonists on Kidney Outcomes Among Patients With Type 2 Diabetes. Am J Kidney Dis. 2026 Sep; 88(3):366-377.
-
D-Allulose Reduces Weight More Persistently than Oral Semaglutide While Both Equally Elevate Grip Strength in Diet-Induced Obese Mice. Nutrients. 2026 Feb 23; 18(4).
-
Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. J Diabetes Investig. 2026 Apr; 17(4):567-575.
-
Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review. J Sex Med. 2026 Jan 07; 23(2).
-
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract. 2025 Nov; 229:112910.
-
GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study. J Addict Med. 2026 May-Jun 01; 20(3):375-380.
-
Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide. Ophthalmol Retina. 2026 Feb; 10(2):142-151.
-
Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study. J Alzheimers Dis. 2025 08; 106(4):1509-1522.
-
Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngol Head Neck Surg. 2025 Aug; 173(2):360-366.
-
Semaglutide and bariatric surgery induce distinct changes in the composition of mouse white adipose tissue. Mol Metab. 2025 May; 95:102126.